- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04139018
Timolol Gel for Epistaxis in Hereditary Hemorrhagic Telangiectasia (ETIC-HHT)
Efficacy of a Timolol Gel in the Care for Epistaxis in Patients With Hereditary Hemorrhagic Telangiectasia: A Double-Blinded, Randomized Controlled Trial
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This study is a double-blinded, placebo-controlled, 8-week randomized clinical trial investigating the efficacy of timolol gel in the management of epistaxis in adults with HHT.
The Specific Aims are to determine in adults with HHT-associated epistaxis:
- If topical timolol gel is more effective than placebo in reducing the frequency and severity of epistaxis.
- If topical timolol gel is more effective than placebo in improving hemoglobin levels.
- The frequency of adverse events, side effects, and safety profile of topical timolol gel delivered to the nasal mucosa.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Missouri
-
Saint Louis, Missouri, United States, 63110
- Washington University
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Adults ages 20 and older
- Confirmed clinical (meeting at least 3 of the 4 Curaçao Criteria) or genetic diagnosis of HHT
- Epistaxis Severity Score (ESS) ≥ 4 and 2 or more nosebleeds per week with a cumulative nosebleed duration of at least 5 minutes per week
- Stable nasal hygiene and medical regimen for preceding 1 month
- Stable epistaxis pattern over the preceding 3 months
Exclusion Criteria:
Contraindications for systemic β adrenergic blocker administration
- Hypersensitivity to β adrenergic blockers
- Asthma or bronchospasm
- Congestive heart failure with LVEF <40%
- Hereditary pulmonary arterial hypertension
- Baseline bradycardia (HR <55 beats per minute)
- Sick Sinus Syndrome
- 2nd or 3rd degree heart block, left or right bundle branch block, or bifasicular block
- Uncontrolled diabetes mellitus (most recent HbA1c >9%) or diabetic ketoacidosis within last 6 months
- Hypotension (systolic blood pressure < 90)
- Known hypersensitivity to timolol
- Severe peripheral circulatory disturbances (Raynaud phenomenon)
- Known intermediate or poor metabolizer variant of the liver enzyme CYP2D6
- Current use of any of the following known strong CYP2D6 inhibitors: fluoxetine (Prozac), paroxetine (Paxil), bupropion (Welbutrin), quinidine, quinine, ritonavir (Norvir), and terbinafine (Lamisil)
- Current use of the following other drugs known to pharmacodynamically interact with timolol: diltiazem, verapamil, digoxin, digitalis, propafenone, disopyramide, clonidine, flecainide, or lidocaine
- Patients currently treated or who plan to initiate treatment with β-blockers
- Use of any anti-angiogenic medication in the last month prior to recruitment, including bevacizumab, pazopanib, thalidomide, or lenalidomide
- Illicit drug use, except marijuana
- Known pheochromocytoma
- Use of anticoagulants, antiplatelet, or fibrinolytic therapies within the last month prior to recruitment, except for low-dose (81 mg or less) of aspirin
- Pregnancy or planned pregnancy in the next 6 months or currently breastfeeding
- Inability to read or understand English
- Inability to complete 8 weeks of therapy for any reason
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Timolol Gel Arm
Participants in the timolol gel arm (active medication arm) will receive timolol nasal gel 0.1% with 0.5 mL applied to each nostril twice daily via a syringe that will amount to a 2 mg total daily dose.
|
Timolol nasal gel 0.1% will be prepared with a poloxamer gel (combination of poloxamer 188 and 407; pH adjusted to 4.5-6.5)
and 0.5 ml applied to each nostril twice daily.
The total daily dose would amount to 2 mg.
|
Placebo Comparator: Placebo Gel Arm
Participants in the placebo gel arm will receive the gel itself with no active medication.
|
Placebo gel is prepared with poloxamers and no active ingredients.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Assisted Epistaxis Severity Scale (aESS) Score From Baseline at 8 Week Follow-up
Time Frame: Baseline to 8-week follow-up
|
Assessment of epistaxis severity will be obtained by the validated instrument, the Epistaxis Severity Score (ESS). To complete the ESS, patients are asked to consider typical symptoms over the previous 3 months. The ESS contains 6 items - frequency, duration, and intensity of nosebleeds, whether patient has sought medication attention, whether patient is anemic, and whether patient has received a blood transfusion. The overall score ranges from 0 to 10, with severity of nosebleed based on score graded as None composite score of 0-1, Mild 1-4, Moderate 4-7, and Severe as 7-10.The minimal important difference noticeable by both patients and clinicians in the ESS scoring system is estimated as a change of 0.71. The scoring and MCID of the aESS is the same as the ESS. The aESS references a participant's epistaxis over the past 1 month, and the change in aESS was calculated as the aESS score at 8 weeks minus the aESS score at baseline. |
Baseline to 8-week follow-up
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants With Improved Response on Clinical Global Impression - Improvement (CGI-I) Scale
Time Frame: Scores at 8-week follow-up only
|
CGI-I is a global rating of improvement scale, which requires subjects to rate their degree of improvement on a seven-point scale: "Compared to your condition at admission to the project [prior to medication initiation], how would you rate your overall response: 1=very much improved since the initiation of treatment; 2=much improved; 3=minimally improved; 4=no change from baseline (the initiation of treatment); 5=minimally worse; 6= much worse; 7=very much worse since the initiation of treatment."
|
Scores at 8-week follow-up only
|
Collaborators and Investigators
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Pathologic Processes
- Cardiovascular Diseases
- Vascular Diseases
- Respiratory Tract Diseases
- Congenital Abnormalities
- Hematologic Diseases
- Hemorrhage
- Hemorrhagic Disorders
- Otorhinolaryngologic Diseases
- Hemostatic Disorders
- Signs and Symptoms, Respiratory
- Nose Diseases
- Cardiovascular Abnormalities
- Vascular Malformations
- Epistaxis
- Telangiectasis
- Telangiectasia, Hereditary Hemorrhagic
- Physiological Effects of Drugs
- Adrenergic beta-Antagonists
- Adrenergic Antagonists
- Adrenergic Agents
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Anti-Arrhythmia Agents
- Antihypertensive Agents
- Timolol
Other Study ID Numbers
- 201908160
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hereditary Hemorrhagic Telangiectasia
-
Vaderis Therapeutics AGRecruitingHereditary Hemorrhagic Telangiectasia (HHT)United States, Spain, France, Belgium, Netherlands, Italy
-
Unity Health TorontoSunnybrook Health Sciences Centre; University of Pittsburgh; Duke University; Barrow... and other collaboratorsActive, not recruitingHereditary Hemorrhagic Telangiectasia (HHT)Canada
-
Imperial College LondonCompletedHereditary Hemorrhagic Telangiectasia (HHT)United Kingdom
-
University Hospital, EssenCompletedHereditary Haemorrhagic Telangiectasia (HHT)Germany
-
University of PennsylvaniaCompletedHereditary Hemorrhagic Telangiectasia (HHT)United States
-
University Hospital, EssenCompleted
-
Centre Hospitalier Universitaire DijonCompletedHereditary Hemorrhagic TelangiectasiaFrance
-
Hospices Civils de LyonCompletedHHT | Hemorrhagic Hereditary TelangiectasiaFrance
-
Hospices Civils de LyonCompletedLiver Transplant | Hereditary Haemorrhagic Telangiectasia
-
Unity Health TorontoThe Hospital for Sick Children; Sunnybrook Health Sciences Centre; National Institute... and other collaboratorsCompletedHereditary Hemorrhagic TelangiectasiaCanada
Clinical Trials on Timolol Gel
-
Kanecia Obie ZimmermanNational Institutes of Health (NIH); The Emmes Company, LLCCompletedInfantile HemangiomaUnited States
-
Vistakon PharmaceuticalsCompletedOcular Hypertension | Glaucoma, Open AngleUnited States
-
Rady Children's Hospital, San DiegoValeant PharmaceuticalsCompleted
-
Children's Hospital of PhiladelphiaSociety for Pediatric DermatologyWithdrawn
-
Brigham and Women's HospitalCompletedSurgical Wound | Wound Heal | Wound of Skin | Wound OpenUnited States
-
Brigham and Women's HospitalTerminatedSurgical Wound | Wound Heal | Wound of Skin | Full Thickness Skin Graft HealingUnited States
-
Laboratoires TheaCompletedOcular Hypertension GlaucomaBulgaria
-
Fraser HealthWithdrawnIschemic Optic Neuropathy | Optic Neuropathy, Ischemic | Anterior Ischemic Optic Neuropathy | Optic Neuropathy, Anterior IschemicCanada
-
ForSight Vision5, Inc.CompletedOcular Hypertension | Open-Angle GlaucomaPanama
-
Afyon Kocatepe University HospitalCompleted